Human Pilot Study - HA35 (Hyaluronan Molecular Weight 35) Dietary Supplement for Promoting Intestinal Health
NCT ID: NCT02867605
Last Updated: 2020-09-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2016-07-31
2019-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy of a Probiotic for Antibiotic Associated Gastrointestinal Symptoms
NCT05845073
Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study
NCT06433310
Synbiotic Dietary Supplement and Gut Microbiota
NCT04097106
The Effect of Probiotic Intervention on Intestinal Permeability
NCT03027583
A Trial of a Multi-Component Nutritional Supplement in Hydrogen-Dominant Small Intestinal Bacterial Overgrowth
NCT07215676
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Controls ages 18-45 with BMI of 19-25 or 30-35
Single Arm study
Hyaluronan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hyaluronan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-45 years old
* Willingness to take oral supplement and adhere to study requirements
Exclusion Criteria
* Oral antibiotics within 4 weeks of study initiation
* History of cardiac disease, and medications for cardiac disease
* Use statins and antihypertensive drugs
* Inflammatory bowel disease including irritable bowel syndrome
* History of intestinal surgery, excluding hernia repair and appendectomy
* Active cancer diagnosis (except skin cancer)
* Chronic acid suppression treatment (proton pump inhibitors, histamine H2 receptor antagonists)
* Immune modulatory treatments (e.g. chronic immunosuppressive medications, chronic NSAIDs)
* Vegetarian or vegan diet7
* Abnormal liver or kidney function as measured by routine serum chemistry testing
* Severe anemia or significant white blood cell or platelet abnormalities
* No additional blood or blood product donations during the study
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Cleveland Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Carol De La Motte
Assoiciate Staff
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hill DR, Kessler SP, Rho HK, Cowman MK, de la Motte CA. Specific-sized hyaluronan fragments promote expression of human beta-defensin 2 in intestinal epithelium. J Biol Chem. 2012 Aug 31;287(36):30610-24. doi: 10.1074/jbc.M112.356238. Epub 2012 Jul 3.
Hill DR, Rho HK, Kessler SP, Amin R, Homer CR, McDonald C, Cowman MK, de la Motte CA. Human milk hyaluronan enhances innate defense of the intestinal epithelium. J Biol Chem. 2013 Oct 4;288(40):29090-104. doi: 10.1074/jbc.M113.468629. Epub 2013 Aug 15.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-142
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.